A Multicentre, Randomized, Double-Blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of DNV001 Injection at Different Dosages in Patients With Primary Hypercholesterolaemia or Mixed Hyperlipidaemia and Elevated Low Density Lipoprotein Cholesterol (LDL-C) Inadequate
Latest Information Update: 11 Feb 2026
At a glance
- Drugs DNV 001 (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus First in man; Therapeutic Use
Most Recent Events
- 11 Feb 2026 New trial record